IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4134
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$38M
Ram Mukunda
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Headcount
61
HQ Base
BETHESDA, Maryland
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$IGC IGC Pharma, Inc. | 35 | 24 | 29 | 30 | - | - | -83.2% | -69.1% | 48.4% | -776.6% | -586.3% | -6.4% | 0.0% | 20.0x | $38M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
IGC Pharma, Inc. (IGC) receives a "Avoid" rating with a composite score of 34.8/100. It ranks #4134 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IGC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 24 | 6 | +18ALPHA |
| MOMENTUM | 30 | 18 | +12ALPHA |
| VALUATION | 29 | 19 | +10ALPHA |
| INVESTMENT | 36 | 63 | -27DRAG |
| STABILITY | 65 | 64 | +1NEUTRAL |
| SHORT INT | 49 | 48 | +1NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -83.2% (sector -1.9%)
GM 48% vs sector 44%, OM -777% vs sector 3%
Capital turnover N/A, R&D intensity 469.9%
Rev growth -6%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate IGC Pharma, Inc. (IGC) as Avoid with a composite score of 34.8/100 at a current price of $0.28. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
IGC Pharma, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.8/100 places it at rank #4134 in our full universe.
No Moat
Medium
Poor
Fair Value
Gross margins of 48% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
IGC Pharma, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags IGC Pharma, Inc. with an Avoid rating, assigning a composite score of 34.8/100 and 1 out of 5 stars. Ranked #4134 of 7,333 stocks, IGC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
IGC Pharma, Inc. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -83.2% (sector avg: -1.9%), gross margins of 48.4% (sector avg: 44.1%), net margins of -586.3% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
IGC registers a value score of just 29/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.05x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
IGC Pharma, Inc.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -6.4% vs. a sector average of 6.7% and a return on assets of -69.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IGC is currently showing below-average momentum at 30/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -6.4% year-over-year, while a beta of 0.54 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
IGC shows good financial stability with a score of 65/100. Key stability metrics include a beta of 0.54 and a debt-to-equity ratio of 20.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 49/100 for IGC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 20.00x), micro-cap liquidity risk. With a $38M market cap (micro-cap), IGC Pharma, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
IGC Pharma, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4134 of 7,333 overall (44th percentile). Key comparisons include ROE of -83.2% trailing the -1.9% sector median and operating margins of -776.6% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IGC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (24) would have the largest impact on the composite score.
ROE 4281% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 10% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 31042% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company. Mullen Automotive, Inc. (NASDAQ: MULN) shares gained 52.8% to $0.2612 in pre-market trading. Mullen Automotive shares jumped 69% on Wednesday after the company announced the retention of a law group to investigate possible naked short selling. Micromobility.com Inc. (NASDAQ: MCOM) shares rose 19.8% to $0.1354 in pre-market trading. micromobility.com recently announced a strategic realignment to strengthen its financial position and drive profitability. Caravelle International Group (NASDAQ: CACO) rose 19.6% to $0.6399 in pre-market trading. AIM ImmunoTech Inc. (NYSE: AIM) gained 18.3% to $0.7690 in pre-market trading after declining 3% on Wednesday. Histogen Inc. (NASDAQ: HSTO) rose 18% to $0.8563 in pre-market trading. Histogen announced its decision to pause further development of its programs and commence a process to explore strategic alternatives. IGC Pharma, Inc. (NYSE: IGC) shares rose 14.7% to $0.39 in pre-market trading after gaining around 5% on Wednesday. IronNet, Inc. (NYSE: IRNT) shares climbed 13.9% to $0.2392 in pre-market trading after gaining ...
IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease dementia. VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized patient populations while maintaining continuity of clinical care. IGC Pharma believes this practice-integrated mo
POTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to ...